{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T03:30:45Z","timestamp":1794281445229,"version":"4.9.0"},"reference-count":30,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["T32GM008562"],"award-info":[{"award-number":["T32GM008562"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ajogmfm.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Obstetrics & Gynecology MFM"],"published-print":{"date-parts":[[2019,3]]},"DOI":"10.1016\/j.ajogmf.2019.03.001","type":"journal-article","created":{"date-parts":[[2019,3,27]],"date-time":"2019-03-27T15:22:41Z","timestamp":1553700161000},"page":"50-62","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":29,"title":["Oral progesterone for the prevention of recurrent preterm birth: systematic review and metaanalysis"],"prefix":"10.1016","volume":"1","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3705-6943","authenticated-orcid":false,"given":"Rupsa C.","family":"Boelig","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0584-2181","authenticated-orcid":false,"given":"Luigi","family":"Della Corte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9586-8309","authenticated-orcid":false,"given":"Sherif","family":"Ashoush","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6695-390X","authenticated-orcid":false,"given":"David","family":"McKenna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0078-2113","authenticated-orcid":false,"given":"Gabriele","family":"Saccone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3721-6350","authenticated-orcid":false,"given":"Shalini","family":"Rajaram","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincenzo","family":"Berghella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ajogmf.2019.03.001_bib1","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1056\/NEJMoa035140","article-title":"Prevention of recurrent preterm delivery by 17 alpha-hydroxyprogesterone caproate","volume":"348","author":"Meis","year":"2003","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ajogmf.2019.03.001_bib2","doi-asserted-by":"crossref","first-page":"374.e1","DOI":"10.1016\/j.ajog.2015.12.054","article-title":"Racial and ethnic disparities in use of 17-alpha hydroxyprogesterone caproate for prevention of preterm birth","volume":"214","author":"Yee","year":"2016","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ajogmf.2019.03.001_bib3","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1053\/j.semperi.2014.08.013","article-title":"Prevention of preterm delivery with 17-hydroxyprogesterone caproate: pharmacologic considerations","volume":"38","author":"Feghali","year":"2014","journal-title":"Semin Perinatol"},{"key":"10.1016\/j.ajogmf.2019.03.001_bib4","doi-asserted-by":"crossref","first-page":"600.e1","DOI":"10.1016\/j.ajog.2017.02.025","article-title":"17-alpha Hydroxyprogesterone caproate did not reduce the rate of recurrent preterm birth in a prospective cohort study","volume":"216","author":"Nelson","year":"2017","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ajogmf.2019.03.001_bib5","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1002\/uog.17245","article-title":"Vaginal progesterone versus intramuscular 17-alpha-hydroxyprogesterone caproate for prevention of recurrent spontaneous preterm birth in singleton gestations: a systematic review and meta-analysis of randomized controlled trials","volume":"49","author":"Saccone","year":"2017","journal-title":"Ultrasound Obstet Gynecol"},{"key":"10.1016\/j.ajogmf.2019.03.001_bib6","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1016\/j.steroids.2003.08.003","article-title":"All progestins are not created equal","volume":"68","author":"Stanczyk","year":"2003","journal-title":"Steroids"},{"key":"10.1016\/j.ajogmf.2019.03.001_bib7","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1016\/S0015-0282(16)54713-X","article-title":"Comparative bioavailability of orally and vaginally administered progesterone","volume":"56","author":"Norman","year":"1991","journal-title":"Fertil Steril"},{"key":"10.1016\/j.ajogmf.2019.03.001_bib8","series-title":"Cochrane handbook for systematic reviews of interventions, version 5.1.0","year":"2011"},{"key":"10.1016\/j.ajogmf.2019.03.001_bib9","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.jclinepi.2010.07.015","article-title":"GRADE guidelines: 3, rating the quality of evidence","volume":"64","author":"Balshem","year":"2011","journal-title":"J\u00a0Clin Epidemiol"},{"key":"10.1016\/j.ajogmf.2019.03.001_bib10","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1111\/aogs.13236","article-title":"The value of oral micronized progesterone in the prevention of recurrent spontaneous preterm birth: a randomized controlled trial","volume":"96","author":"Ashoush","year":"2017","journal-title":"Acta Obstet Gynecol Scand"},{"key":"10.1016\/j.ajogmf.2019.03.001_bib11","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1055\/s-0031-1274509","article-title":"A\u00a0randomized trial of micronized progesterone for the prevention of recurrent preterm birth","volume":"28","author":"Glover","year":"2011","journal-title":"Am J Perinatol"},{"key":"10.1016\/j.ajogmf.2019.03.001_bib12","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.ijgo.2008.08.029","article-title":"Oral micronized progesterone for prevention of preterm birth","volume":"104","author":"Rai","year":"2009","journal-title":"Int J Gynecol Obstet"},{"key":"10.1016\/j.ajogmf.2019.03.001_bib13","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1097\/AOG.0b013e3182699a15","article-title":"Progestogens for preterm birth prevention: a systematic review and meta-analysis","volume":"120","author":"Likis","year":"2012","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.ajogmf.2019.03.001_bib14","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1007\/s00404-013-2789-9","article-title":"Progestogens for preterm birth prevention: a systematic review and meta-analysis by drug route","volume":"287","author":"Velez Edwards","year":"2013","journal-title":"Arch Gynecol Obstet"},{"key":"10.1016\/j.ajogmf.2019.03.001_bib15","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1111\/1471-0528.15566","article-title":"Vaginal progesterone, oral progesterone, 17-OHPC, cerclage, and pessary for preventing preterm birth in at-risk singleton pregnancies: an updated systematic review and network meta-analysis","volume":"126","author":"Jarde","year":"2019","journal-title":"BJOG"},{"key":"10.1016\/j.ajogmf.2019.03.001_bib16","first-page":"CD004947","article-title":"Prenatal administration of progesterone for preventing preterm birth in women considered to be at risk of preterm birth","volume":"7","author":"Dodd","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.ajogmf.2019.03.001_bib17","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1093\/humupd\/6.2.139","article-title":"Comparison between different routes of progesterone administration as luteal phase support in infertility treatments","volume":"6","author":"Tavaniotou","year":"2000","journal-title":"Hum Reprod Update"},{"key":"10.1016\/j.ajogmf.2019.03.001_bib18","first-page":"403","article-title":"Direct transport of progesterone from vagina to uterus","volume":"95","author":"Cicinelli","year":"2000","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.ajogmf.2019.03.001_bib19","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1055\/s-0032-1316444","article-title":"The safety of progesterone and 17-hydroxyprogesterone caproate administration for the prevention of preterm birth: an evidence-based assessment","volume":"29","author":"O\u2019Brien","year":"2012","journal-title":"Am J Perinatol"},{"issue":"suppl","key":"10.1016\/j.ajogmf.2019.03.001_bib20","first-page":"305","article-title":"Treatment with different types of progesterone in\u00a0prevention of preterm delivery","volume":"23","author":"Ndoni","year":"2010","journal-title":"J Matern Neonatal Med"},{"key":"10.1016\/j.ajogmf.2019.03.001_bib21","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1097\/01.ogx.0000456349.39722.4e","article-title":"Maintenance tocolysis with oral micronized progesterone for prevention of preterm birth after arrested preterm labor","volume":"69","author":"Choudhary","year":"2015","journal-title":"Obstet Gynecol Surv"},{"key":"10.1016\/j.ajogmf.2019.03.001_bib22","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/0028-2243(91)90118-5","article-title":"The use of micronized progesterone in the treatment of menace of preterm delivery","volume":"40","author":"Noblot","year":"1991","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"10.1016\/j.ajogmf.2019.03.001_bib23","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.1080\/14767058.2017.1330406","article-title":"Effectiveness of dydrogesterone, 17-OH progesterone and micronized progesterone in prevention of preterm birth in women with a short cervix","volume":"31","author":"Pustotina","year":"2018","journal-title":"J\u00a0Matern Neonatal Med"},{"key":"10.1016\/j.ajogmf.2019.03.001_bib24","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/bs.ctdb.2017.03.001","article-title":"Progesterone receptor signaling in uterine myometrial physiology and preterm birth","volume":"125","author":"Wu","year":"2017","journal-title":"Curr Top Dev Biol"},{"key":"10.1016\/j.ajogmf.2019.03.001_bib25","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1053\/j.semperi.2017.07.013","article-title":"Pathophysiology of preterm labor with intact membranes","volume":"41","author":"Talati","year":"2017","journal-title":"Semin Perinatol"},{"key":"10.1016\/j.ajogmf.2019.03.001_bib26","doi-asserted-by":"crossref","first-page":"622.e1","DOI":"10.1016\/j.ajog.2016.07.013","article-title":"Nonresponse to 17-alpha hydroxyprogesterone caproate for recurrent spontaneous preterm birth prevention: clinical prediction and generation of a risk scoring system","volume":"215","author":"Manuck","year":"2016","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ajogmf.2019.03.001_bib27","doi-asserted-by":"crossref","first-page":"844.e1","DOI":"10.1016\/j.ajog.2015.08.014","article-title":"Does 17-alpha hydroxyprogesterone caproate prevent recurrent preterm birth in obese women?","volume":"213","author":"Heyborne","year":"2015","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ajogmf.2019.03.001_bib28","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/j.clinthera.2015.01.007","article-title":"17\u03b1-Hydroxyprogesterone caproate access in the Louisiana Medicaid population","volume":"37","author":"Orsulak","year":"2015","journal-title":"Clin Ther"},{"key":"10.1016\/j.ajogmf.2019.03.001_bib29","doi-asserted-by":"crossref","first-page":"536.e1","DOI":"10.1016\/j.ajog.2015.10.148","article-title":"Patient characteristics associated with 17-alpha hydroxyprogesterone caproate use among a high-risk cohort","volume":"214","author":"Turitz","year":"2016","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ajogmf.2019.03.001_bib30","unstructured":"AMAG Pharmaceuticals announces topline results from the PROLONG trial evaluating Makena (hydroxyprogesterone caproate injection). AMAG Pharmaceuticals. Available at:\u00a0https:\/\/www.amagpharma.com\/news\/amag-pharmaceuticals-announces-topline-results-from-the-prolong-trial-evaluating-makena-hydroxyprogesterone-caproate-injection\/. Accessed March 29, 2019."}],"updated-by":[{"DOI":"10.1016\/j.ajogmf.2025.101752","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000}}],"container-title":["American Journal of Obstetrics & Gynecology MFM"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589933319300084?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589933319300084?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T23:45:14Z","timestamp":1762904714000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589933319300084"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,3]]}},"alternative-id":["S2589933319300084"],"URL":"https:\/\/doi.org\/10.1016\/j.ajogmf.2019.03.001","relation":{},"ISSN":["2589-9333"],"issn-type":[{"value":"2589-9333","type":"print"}],"subject":[],"published":{"date-parts":[[2019,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Oral progesterone for the prevention of recurrent preterm birth: systematic review and metaanalysis","name":"articletitle","label":"Article Title"},{"value":"American Journal of Obstetrics & Gynecology MFM","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ajogmf.2019.03.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}